Recent News

• 09.04.2025 - BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.19.2025 - BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
• 08.13.2025 - BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
• 08.06.2025 - BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
• 07.14.2025 - BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
• 07.08.2025 - BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

Recent Filings

• 08.28.2025 - DEF 14A Other definitive proxy statements
• 08.28.2025 - ARS Annual Report to Security Holders
• 08.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.19.2025 - 8-K Current report
• 08.15.2025 - PRE 14A Other preliminary proxy statements
• 08.13.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 8-K Current report
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors